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A B S T R A C TObjectives: Adjuvant chemotherapy decisions in early breast cancer
are complex. The 21-gene assay can potentially aid such decisions,
but costs US $4175 per patient. Adjuvant! Online is a freely available
decision aid. We evaluate the cost-effectiveness of using the 21-gene
assay in conjunction with Adjuvant! Online, and of providing adju-
vant chemotherapy conditional upon risk classification. Methods: A
probabilistic Markov decision model simulated risk classification,
treatment, and the natural history of breast cancer in a hypothetical
cohort of 50-year-old women with lymph node–negative, estrogen
receptor– and/or progesterone receptor–positive, human epidermal
growth factor receptor 2/neu–negative early breast cancer. Cost-
effectiveness was considered from an Ontario public-payer perspec-
tive by deriving the lifetime incremental cost (2012 Canadian dollars)
per quality-adjusted life-year (QALY) for each strategy, and the
probability each strategy is cost-effective, assuming a willingness-
to-pay of $50,000 per QALY. Results: The 21-gene assay has an
incremental cost per QALY in patients at low, intermediate, or highsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.03.1625
lden@theta.utoronto.ca.
ondence to: Mike Paulden, THETA Collaborative, UAdjuvant Online! risk of $22,440 (probability cost-effective 78.46%),
$2,526 (99.40%), or $1,111 (99.82%), respectively. In patients at low
(high) 21-gene assay risk, adjuvant chemotherapy increases (reduces)
costs and worsens (improves) health outcomes. For patients at
intermediate 21-gene assay risk and low, intermediate, or high
Adjuvant! Online risk, chemotherapy has an incremental cost
per QALY of $44,088 (50.59%), $1,776 (77.65%), or $1,778 (82.31%),
respectively. Conclusions: The 21-gene assay appears cost-effective,
regardless of Adjuvant! Online risk. Adjuvant chemotherapy appears
cost-effective for patients at intermediate or high 21-gene assay risk,
although this finding is uncertain in patients at intermediate 21-gene
assay and low Adjuvant! Online risk.
Keywords: breast cancer, chemotherapy, cost-effectiveness analysis,
decision making, pharmacogenetics.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Adjuvant chemotherapy decisions for women with early stage
breast cancer are complex. At present, decisions are informed by
clinical judgment, often supplemented through the use of Adju-
vant! Online [1]. Adjuvant! Online is a free online diagnostic tool
that estimates a woman’s risk of breast cancer–specific mortality
(BCSM) or relapse on the basis of information entered by the
physician, including the woman’s age, comorbidities, tumor size,
estrogen receptor status, number of involved lymph nodes, and
proposed course of treatment [2]. Results can be categorized as
‘‘low’’ (BCSMo 9%), ‘‘intermediate’’ (9%r BCSMo 17%), or ‘‘high’’
(BCSMZ 17%) risk [3]. A validation study of Adjuvant! Online has
found a high degree of correlation between predicted and
observed survival [4].
An alternative predictive tool has recently become available. The
21-gene assay (Oncotype DX, Genomic Health, Redwood City, CA)
quantifies the expression of 21 genes in breast cancer tissue byperforming reverse transcription polymerase chain reaction on
formalin-fixed paraffin-embedded tumor blocks that are obtained
during initial surgery. Results are summarized by a ‘‘Recurrence
Score’’ (RS) between 0 and 100, with scores categorized as ‘‘low’’
(RSo 18), ‘‘intermediate’’ (18r RSo 30), or ‘‘high’’ (RSZ 30) risk [5].
It has been validated both in women with estrogen receptor–
positive early stage breast cancer that is lymph node–negative,
and in women with estrogen receptor–positive breast cancer that
is lymph node–positive, as a means to predict the risk of distant
recurrence and magnitude of chemotherapy benefit when added to
endocrine therapy [6–9].
As of April 2012, the 21-gene assay cost US $4175 per patient
[10]. Its cost-effectiveness is therefore a matter of considerable
policy interest. There is also uncertainty as to the clinical-
and cost-effectiveness of providing adjuvant chemotherapy, par-
ticularly to patients at intermediate risk [11,12]. We present a
cost-effectiveness analysis that comprehensively addresses both
these issues. An earlier version of our analysis formed part of aSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
niversity of Toronto, 144 College Street, Toronto, ON M5S 3M2,
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Ontario Ministry of Health and Long-Term Care [13].Methods
Overview
We conducted a cost-effectiveness analysis from the perspective
of the Ontario Ministry of Health and Long-Term Care. The
analysis had two objectives:1.Fig
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effectiveness of the 21-gene assay, when used in conjunction
with Adjuvant! Online.2. To evaluate the outcomes, costs, effectiveness, and cost-
effectiveness of providing adjuvant chemotherapy, condi-
tional upon a patient’s predicted risk of distant recurrence.
The patient population was a hypothetical cohort of 50-year-
old women diagnosed with lymph node–negative, estrogen
receptor– and/or progesterone receptor– positive, human epider-
mal growth factor receptor 2 (HER2/neu)–negative early breast
cancer, who are candidates for adjuvant chemotherapy. The
cohort was followed over a lifetime. Costs were measured in
2012 Canadian dollars, and a discount rate of 5% was applied to
costs and outcomes [14]. The analysis was conducted in
April 2012.. 1 – Model schematic. (A) Decision tree representing the risk
cision nodes are represented by squares, while chance node
vide the 21-gene assay is made independently for each Adjuv
o three possible risk groups when provided (‘‘low,’’ ‘‘int.,’’ an
/A’’). Because patients in the N/A risk group face a different r
d high-risk groups, the model considers four unique risk grou
-gene assay. Because patients in any one of the three Adjuvan
-gene assay risk groups, the model assigns each patient to 1
resents a unique combination of the Adjuvant! Online and 2
cision is considered independently for each of the 12 risk ca
resenting patients’ progression through risk classification an
tant recurrence, and death. Int., intermediate; N/A, not availWe conducted our analysis in consultation with an expert
panel convened by the Ontario Ministry of Health and Long-Term
Care [15]. The expert panel provided input on the appropriate
model structure and parameters.Model
The model is described in Figure 1. The structure was informed
by an existing model by Tsoi et al. [16]. Patients were first
stratified by Adjuvant! Online risk group. Each Adjuvant! Online
risk group might then be provided with the 21-gene assay; if
provided, the respective Adjuvant! Online risk group was further
stratified by 21-gene assay risk group. This resulted in patients
being assigned to 1 of 12 risk categories (see Fig. 1 legend). All
patients were then assumed to undertake adjuvant tamoxifen
treatment for 5 years, with some patients also receiving adjuvant
chemotherapy. Higher risk patients were assumed to receive
more complex chemotherapy regimens, as detailed below. All
chemotherapy patients risked toxicity requiring hospital treat-
ment. Patients were initially assumed to be distant recurrence
free, but risked developing a distant recurrence over their life-
time. All patients eventually died, either because of breast cancer
or for other reasons. The model was developed by using TreeAge
Pro 2009 (TreeAge Software, Inc., Williamstown, MA), Microsoft
Excel 2010 (Microsoft, Seattle, WA), and WinBUGS 1.4.3 (MRC
Biostatistics Unit, Cambridge, UK).classification process and adjuvant chemotherapy decision.
s are represented by circles. The decision about whether to
ant! Online risk group. The 21-gene assay stratifies patients
d ‘‘high’’) or one possible risk group when not provided
isk of distant recurrence to patients in any of the low-, int.-,
ps resulting from the decision to provide or not provide the
t! Online risk groups may be assigned to any one of the four
of 12 (3  4) unique risk ‘‘categories.’’ Each risk category
1-gene assay risk groups. The adjuvant chemotherapy
tegories resulting from risk classification. (B) Markov model
d the possible provision of adjuvant chemotherapy, possible
able.
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The model parameters are summarized in Table 1.
Probabilities
Proportion of patients assigned to each risk category. The
proportion of patients assigned to each of the 12 risk categories
was estimated from Bryant’s retrospective analysis of Adjuvant!
Online and the 21-gene assay as predictors of 10-year distant
recurrence by using data and samples gathered from a subset of
668 patients enrolled in the tamoxifen arm of the NSABP B-14
study (see Appendix A in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2013.03.1625) [3,6].
Proportion of patients in each risk category provided adjuvant
chemotherapy. A number of studies have attempted to measure
the impact of the 21-gene assay on adjuvant clinical decision
making [17,32–35]. The study by Lo et al. [17] is the only prospec-
tive study in a North American population that reports the
proportion of patients assigned to receive chemotherapy before
and after the 21-gene assay results are known, stratified by 21-
gene assay risk group. Because the authors did not report the
proportion of patients assigned to receive chemotherapy for each
of the 12 risk categories in our model, we estimated the proportion
for each risk category by using linear regression to derive a
relationship between the baseline risk of distant recurrence and
the proportion of patients assigned to receive chemotherapy.
Because knowledge of the 21-gene assay results has the potential
to change clinician behavior, separate relationships were esti-
mated for before and after the results are known (see Appendix
B in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2013.03.1625).
Choice of Treatment. All patients were assumed to be provided
20 mg tamoxifen treatment daily for 5 years. Some patients were
also assumed to be provided adjuvant chemotherapy, with a
greater proportion of patients assumed to receive adjuvant
chemotherapy in risk categories at higher baseline risk of distant
recurrence. Following advice from the expert panel, higher risk
patients were assumed to receive more complex chemotherapy
regimens.
Patients in the 21-gene assay low-risk group provided
with adjuvant chemotherapy were assumed to receive CMF
chemotherapy: oral cyclophosphamide 100 mg/m2, methotrexate
40 mg/m2, and 5-fluorouracil 600 mg/m2, given 4-weekly for six
cycles.
Adjuvant chemotherapy patients in the 21-gene assay intermedi-
ate risk group were assumed to receive TC chemotherapy: docetaxel
75mg/m2 and cyclophosphamide 600mg/m2, given 3-weekly for four
cycles. The Ontario Ministry of Health and Long-Term Care funds
secondary prophylactic granulocyte colony-stimulating factor
(G-CSF) prophylaxis with filgrastim for some low-income patients
and those older than 65 years (assumed to account for 40% of all
patients). It was assumed that 33% of TC chemotherapy patients
would require secondary G-CSF prophylaxis [36].
Adjuvant chemotherapy patients in the 21-gene assay high-
risk group were assumed to receive FEC-D chemotherapy:
5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophos-
phamide 500 mg/m2 (FEC), given 3-weekly for three cycles, followed
by docetaxel 100 mg/m2 given 3-weekly for three cycles. For FEC-D
chemotherapy, the Ontario Ministry of Health and Long-Term Care
funds primary G-CSF prophylaxis with filgrastim alongside doce-
taxel and secondary G-CSF prophylaxis alongside FEC and doce-
taxel. It was assumed that patients funded by the Ministry (40% of
all patients) would receive primary G-CSF prophylaxis alongsidedocetaxel and that 15% of these patients would receive secondary
G-CSF prophylaxis alongside FEC or docetaxel.
G-CSF prophylaxis was assumed to consist of 300 mcg
filgrastim per day for 10 days, provided alongside half of chemo-
therapy cycles [37].
For adjuvant chemotherapy patients not provided with the
21-gene assay, the choice of chemotherapy regimen was assumed
to be determined in a similar manner by the Adjuvant! Online
risk group.
Risk of Hospital Visit Due to Chemotherapy Toxicity. A propor-
tion of patients undergoing chemotherapy was assumed to
require a hospital admission due to toxicity. Recent data on the
proportion of breast cancer patients visiting the hospital within 4
weeks of any cycle of adjuvant chemotherapy were obtained from
the Canadian Institute for Health Information [18].
Risk of Distant Recurrence. There are no published prospective
studies reporting distant recurrence conditional upon 21-gene
assay or Adjuvant! Online risk. The retrospective analysis by
Bryant [3] using data from a subset of 668 patients enrolled in
the tamoxifen arm of the NSABP B-14 study reported esti-
mates of the risk of distant recurrence without adjuvant
chemotherapy for some (but not all) of the risk categories in
our model. A further retrospective analysis by Paik et al. [7]
provided estimates of the risk of distant recurrence with and
without CMF chemotherapy, using data and samples gathered
from a subset of 651 patients enrolled in the NSABP B-20
study. These results were stratified by 21-gene assay risk
group only.
We used the findings from Bryant and Paik et al. to derive the
10-year risk of distant recurrence without adjuvant chemother-
apy for each risk category. The distant recurrence-free survival
curves reported by Bryant revealed considerable overlap between
the intermediate and high Adjuvant! Online risk groups. There-
fore, a common risk of distant recurrence was assumed for both
risk groups. In reporting estimates of the risk of distant recur-
rence, Bryant merged the intermediate and high 21-gene assay
risk groups. We imputed separate estimates for each by using a
calibration model developed in WinBUGS (see Appendix C in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2013.03.1625).
The Ontario-based expert panel, however, expressed
concern that the average risk of 10-year distant recurrence of
14.8% observed in the subset of the NSABP B-14 study analyzed
by Bryant was likely to be higher than that in the current
Ontario target population. The lower average risk of 11.4%
observed in the subset of the NSABP B-20 study analyzed by
Paik was regarded as more appropriate for Ontario. We
therefore applied a proportional adjustment to the estimate
for each risk category so that the aggregate risk of distant
recurrence across each 21-gene assay risk group was commen-
surate with the estimates reported by Paik et al. from the NSABP
B-20 study.
Next, we derived estimates of the relative risk of 10-year
distant recurrence with CMF chemotherapy for each risk cate-
gory. Because the relative risk estimates reported by Paik et al.
were stratified by 21-gene assay risk group only, we developed a
regression model by using WinBUGS and Microsoft Excel to
impute the relative risk for each risk category (see Appendix C
in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2013.03.1625).
Estimates of the 10-year risk of distant recurrence with more
complex chemotherapy regimens were derived by estimating the
relative risk of distant recurrence for TC versus CMF and for FEC-
D versus CMF from the results of published trials (see Appendix C
Table 1 – Model parameters.
Parameter (Distribution*) [Source] Value
Probabilities
Proportion of patients assigned to each risk category (%) (Dirichlet) [3]
Adjuvant! Online low risk
21-gene assay low risk 32.34
21-gene assay intermediate risk 12.57
21-gene assay high risk 8.08
Total for Adjuvant! Online low risk 52.99
Adjuvant! Online intermediate risk
21-gene assay low risk 8.53
21-gene assay intermediate risk 3.59
21-gene assay high risk 6.59
Total for Adjuvant! Online intermediate risk 18.71
Adjuvant! Online high risk
21-gene assay low risk 9.73
21-gene assay intermediate risk 6.14
21-gene assay high risk 12.43
Total for Adjuvant! Online high risk 28.29
Proportion of patients in each risk category provided adjuvant
chemotherapy (%) (Beta) [17]
Adjuvant! Online low risk
21-gene assay low risk 9.79
21-gene assay intermediate risk 17.62
21-gene assay high risk 63.44
21-gene assay not provided 46.05
Adjuvant! Online intermediate risk
21-gene assay low risk 13.73
21-gene assay intermediate risk 36.56
21-gene assay high risk 98.61
21-gene assay not provided 55.06
Adjuvant! Online high risk
21-gene assay low risk 13.72
21-gene assay intermediate risk 36.65
21-gene assay high risk 99.73
21-gene assay not provided 57.57
Risk of hospital visit due to toxicity (%) (Beta) [18] 17.04
Cause of hospital visits due to toxicity (%) (Dirichlet) [18]
Neutropenia/fever/infections 53.56
Injuries & trauma 11.48
Malignant neoplasm 10.89
Pain & pain management 7.51
Nausea/vomiting/dehydration 6.02
Gastrointestinal tract 5.64
Chest pain 4.89
Risk of 10 year distant recurrence without chemotherapy (%) (Beta) [3,7]
Adjuvant! Online low risk
21-gene assay low risk 2.61
21-gene assay intermediate risk 5.78
21-gene assay high risk 24.78
21-gene assay not provided 6.75
Adjuvant! Online intermediate risk
21-gene assay low risk 4.24
21-gene assay intermediate risk 13.40
21-gene assay high risk 45.71
21-gene assay not provided 20.60
Adjuvant! Online high risk
21-gene assay low risk 4.24
21-gene assay intermediate risk 13.40
21-gene assay high risk 45.71
21-gene assay not provided 24.12
Table 1 – continued
Parameter (Distribution*) [Source] Value
Risk of 10 year distant recurrence with chemotherapy (%) (Beta)
[3,7,19–23]
Adjuvant! Online low risk
21-gene assay low risk 3.81
21-gene assay intermediate risk 4.46
21-gene assay high risk 6.48
21-gene assay not provided 4.93
Adjuvant! Online intermediate risk
21-gene assay low risk 4.64
21-gene assay intermediate risk 6.23
21-gene assay high risk 7.37
21-gene assay not provided 6.07
Adjuvant! Online high risk
21-gene assay low risk 5.79
21-gene assay intermediate risk 8.18
21-gene assay high risk 8.91
21-gene assay not provided 7.68
Risk of mortality due to toxicity (%) (Beta) [24] 0.35
Median life expectancy following distant recurrence
(mo) (Normal) [25]
21.0
Risk of mortality due to other causes (Fixed) [26] Life table
Costs (2012 Canadian dollars)
Cost of 21-gene assay (per patient) ($) (Fixed) [10,27]
21-gene assay (2012 US dollars) 4175.00
US/Canadian dollar exchange rate (30 April
2012)
0.9879
21-gene assay (2012 Canadian dollars) 4124.48
Chemotherapy costs applicable to all regimens
(per cycle) ($) (Fixed) [16]
Laboratory tests 62.06
Human resources 147.52
CMF specific costs (per cycle) ($) (Fixed)z
Cyclophosphamide 600 mg/m2 2.26
Methotrexate 40 mg/m2 3.22
5-fluorouracil 600 mg/m2 8.22
TC specific costs (per cycle) ($) (Fixed)z
Docetaxel 75 mg/m2 534.14
Cyclophosphamide 600 mg/m2 39.06
FEC-D specific costs (per cycle) ($) (Fixed)z
5-fluorouracil 500 mg/m2 6.65
Epirubicin 100 mg/m2 80.72
Cyclophosphamide 500 mg/m2 33.23
Docetaxel 100 mg/m2 ¼ 173mg 712.19
G-CSF prophylaxis (per day) ($) (Fixed)z
Filgrastim 300 mcg 184.36
Hormone therapy (per day) ($) (Fixed)z
Tamoxifen 20 mg 0.11
Ongoing care for recurrence-free patients (per month) ($) (Fixed) [28]
1st Year 55.24
2nd Year 49.89
3rd Year 44.54
4th Year 39.19
5th Year and beyond 3.83
Cost of treating distant recurrence ($) (Modeledy) [28]
Initial cost of treatment (one time) 8,356.23
Ongoing care (per month) 717.57
End of life care (last 3 months) ($) (Modeledy) [28] 22,040.96
Treatment of non-fatal chemotherapy toxicity ($) (Log normal) [29]
Neutropenia/fever/infections 6,827.45
Injuries & trauma 8,730.53
Malignant neoplasm 6,754.79
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Fig. 2 – Cost-effectiveness of providing the 21-gene assay.
(A) Total lifetime costs and QALYs of each strategy for the
provision of the 21-gene assay across Adjuvant! Online risk
groups. Label names refer to the Adjuvant! Online risk
groups provided with the 21-gene assay under each
strategy. The black line represents the efficiency frontier.
The slope of the efficiency frontier between pairs of
strategies represents the incremental cost-effectiveness
ratio (ICER) of the more expensive strategy versus the less
expensive strategy. (B) Probability that each strategy for the
provision of the 21-gene assay across Adjuvant! Online risk
groups is cost-effective, conditional upon willingness to pay
for a QALY. Strategies not represented have less than 1%
probability of being cost-effective. QALY, quality-adjusted
life-year.
Table 1 – continued
Parameter (Distribution*) [Source] Value
Pain & pain management 4,352.07
Nausea/vomiting/dehydration 4,142.12
Gastrointestinal tract 6,773.66
Chest pain 3,022.78
Treatment of fatal toxicity ($) (Log normal) [29] 33,807.98
Utility weights
First year following diagnosis (while on
hormone therapy) (Beta) [30]
0.744
First year following diagnosis (while on
chemotherapy) (Beta) [30]
0.620
Second and following years prior to distant
recurrence (Beta) [30]
0.779
Following distant recurrence (Beta) [30] 0.685
Dead (Fixed) [30] 0
Distributions were assigned to parameters according to conven-
tional practice in economic evaluations, as described in the
textbook by Briggs et al. [31]. Probabilities and proportions were
assigned beta distributions (in the case of events with two
outcomes) or Dirichlet distributions (in the case of events with
three or more outcomes). In either case the parameters of the
distribution were informed by the frequency of each outcome
observed in the relevant study. Median life expectancy was
assigned a normal distribution due to the approximately symme-
trical distribution reported by Chang et al. [25]. The costs
associated with treatment of chemotherapy toxicity were
assigned lognormal distributions since the cost data were highly
skewed and positive. Utility weights were assigned beta distribu-
tions to constrain the possible values between 0 and 1, with the
exception of the utility weight for the ‘dead’ state which was
fixed at 0. Where no measure of uncertainty was available, a fixed
value was used. Further details on the distributions assigned to
parameters are available from the authors on request.
y The costs for treating distant recurrence were estimated by
modeling the treatment pathway described in Figure 4 of the
study by Will et al. [28]. To account for parameter uncertainty,
probabilities were assigned beta distributions according to the
number of events at each node implied by the study sample size.
z Princess Margaret Cancer Centre Inpatient and Outpatient Phar-
macy (personal communication, Feb 29, 2012)
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jval.2013.03.1625) [19–23].
Risk of Mortality. The risk of death from causes other than
breast cancer was taken from relevant life tables [26]. Patients
were subject to a higher risk of mortality during chemotherapy
and following distant recurrence [24,25].
Costs
All costs were inflated to 2012 Canadian dollars by using the
Ontario health care inflation index [38].
21-Gene assay. The manufacturer’s list price for the 21-gene
assay was converted to Canadian dollars by using the closing
exchange rate on April 30, 2012 [10,27].
Adjuvant tamoxifen and chemotherapy. The costs associated
with providing adjuvant tamoxifen and chemotherapy were
obtained from the Princess Margaret Cancer Centre Inpatientand Outpatient Pharmacy (personal communication, February 29,
2012).Hospital visit due to chemotherapy toxicity. The costs associ-
ated with hospital visits resulting from chemotherapy toxicity
were estimated from acute inpatient costs collected by the
Ontario Case Costing Initiative [29].Ongoing care, distance recurrence, and terminal care. The
average costs associated with ongoing care prior to distant
recurrence, treatment of distant recurrence, and ongoing and
terminal care following distant recurrence were derived from a
comprehensive study of the lifetime costs of breast cancer treat-
ment in Canada [28].
Table 2 – Outcomes, costs, effectiveness, and cost-effectiveness of providing the 21-gene assay.
A: Outcomes, costs, effectiveness, and cost-effectiveness of providing the 21-gene assay to a population of 1000 patients
Adjuvant! Online
risk groups provided
with 21-gene assay
Outcomes Costs ($ million)y
Provided
21-gene
assay
Provided
adjuvant
chemo
Hospital
visit for
toxicity
10-y
dist.
rec.
10-y
death
Providing
21-gene
assay
Providing
adjuvant
chemo
Incurred
prior to
dist. rec.
None 0 510 87 90 74 0.00 2.37 6.27
High only 283 507 86 72 59 1.23 2.23 6.40
Intermediate only 187 497 84 79 65 0.81 2.41 6.35
Intermediate and high 470 493 84 61 50 2.04 2.27 6.48
Low only 530 371 63 85 70 2.30 2.32 6.37
Low and high 813 368 62 67 55 3.52 2.18 6.49
Low and intermediate 717 358 61 74 62 3.11 2.37 6.45
All 1000 354 60 57 46 4.33 2.23 6.58
B: Incremental outcomes, costs, effectiveness, and cost-effectiveness of providing the 21-gene assay to 1000 patients in each Adjuvant! Online
risk group, compared with not providing the 21-gene assay to 1000 patients in the respective Adjuvant! Online risk group
Adjuvant! Online
risk group provided
with 21-gene assay
Incremental outcomesJ Incremental costs ($ million)z
Provided
21-gene
assay
Provided
adjuvant
chemo
Hospital
visit for
toxicity
10- y
dist.
rec.
10-y
death
Providing
21-gene
assay
Providing
adjuvant
chemo
Incurred
prior to
dist. rec.
Low 1000 262 45 9 7 4.33 0.08 0.18
Intermediate 1000 71 12 56 47 4.33 0.24 0.44
High 1000 2 2 64 53 4.33 0.49 0.45
(Continued on next page)
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Utility weights were derived from the EuroQol five-dimensional
questionnaire index values reported in a recent study of health-
related quality-of-life weights for breast cancer [30].Analyses conducted
We conducted two sets of analyses:1. First, we analyzed the outcomes, costs, effectiveness, and
cost-effectiveness of providing (vs. not providing) the 21-gene
assay to patients in each Adjuvant! Online risk group.2. Next, we analyzed the outcomes, costs, effectiveness, and
cost-effectiveness of providing (vs. not providing) adjuvant
chemotherapy to patients in each of the 12 risk categories.
In each case, parameter uncertainty was accounted for by
conducting probabilistic analysis across 10,000 Monte Carlo
simulations.Results
Providing the 21-Gene Assay
The results of the first analysis are summarized in Figure 2 and
Table 2.
The 21-gene assay is most cost-effective for Adjuvant! Online
high-risk patients, with an incremental cost-effectiveness ratio
(ICER) of $1,111 per quality-adjusted life-year (QALY), followed byAdjuvant! Online intermediate-risk patients ($2,526 per QALY)
and Adjuvant! Online low-risk patients ($22,440 per QALY).
At a typical willingness-to-pay threshold of $50,000 per QALY,
the most cost-effective strategy is to provide the 21-gene assay to
all Adjuvant! Online risk groups. Accounting for parameter
uncertainty, there is a 77.94% likelihood that the 21-gene assay
is cost-effective for all Adjuvant! Online risk groups and a 99.22%
likelihood that it is cost-effective for at least the intermediate and
high Adjuvant! Online risk groups.
Our model projects that providing the 21-gene assay to a
population of 1000 patients would have an upfront cost of
$4.33 million. It would reduce the number of patients receiving
adjuvant chemotherapy by 156, while 27 fewer would be hospi-
talized because of toxicity. The costs associated with chemo-
therapy and hospitalization due to toxicity would fall by $0.14
million. Over 10 years, 33 fewer patients would experience a
distant recurrence and 28 fewer would die of breast cancer.
The costs of treatment following distant recurrence and end-of-
life care would fall by $1.82 million, but the costs of following
up distant recurrence-free patients would increase by $0.31
million, largely because of patients living longer in the distant
recurrence-free state. Total lifetime costs would increase by $2.46
million.
Providing Adjuvant Chemotherapy
The results of the second analysis are summarized in Table 3.
For 21-gene assay low-risk patients, providing adjuvant
chemotherapy increases costs yet results in worse outcomes.
Conversely, for 21-gene assay high-risk patients, adjuvant
chemotherapy improves outcomes and reduces costs.
Table 2 – continued
Effectivenessz Cost-effectiveness of 21-gene assayy
Incurred
following dist.
rec.
Incurred over
last 3 mo of life
Total
lifetime
costs
Life-
years
QALYs ICER Prob. CE
($20k) (%)
Prob. CE
($50k) (%)
Prob. CE
($100k)
(%)
2.64 2.58 13.86 14,311 11,063 N/A 0.06 0.00 0.00
2.17 2.12 14.09 14,580 11,276 $1,111 0.96 0.19 0.08
2.35 2.30 14.19 14,475 11,193 D 0.22 0.07 0.05
1.89 1.84 14.42 14,745 11,407 $2,526 58.51 21.28 11.14
2.47 2.41 15.75 14,407 11,147 D 0.03 0.00 0.00
2.00 1.96 15.99 14,677 11,361 D 0.68 0.41 0.30
2.18 2.13 16.08 14,571 11,278 D 0.14 0.11 0.11
1.72 1.68 16.32 14,841 11,492 $22,440 39.40 77.94 88.32
Incremental
effectiveness#
Cost-effectiveness of 21-gene assay
Incurred
following dist.
rec.
Incurred over
last 3 mo of life
Total
lifetime
costs
Life-
years
QALYs ICER
($)
Prob. CE
($20k) (%)
Prob. CE
($50k) (%)
Prob. CE
($100k)
(%)
0.32 0.31 3.58 181 160 22,440 40.25 78.46 88.73
1.53 1.50 1.77 877 699 2,526 98.27 99.40 99.62
1.64 1.61 0.84 953 755 1,111 99.55 99.82 99.84
CE, cost-effectiveness; chemo, chemotherapy; dist., distant; ICER, incremental cost-effectiveness ratio; Prob., probability; QALY, quality-
adjusted life-year; rec., recurrence.
 Number of events per 1000 patients.
y Costs per 1000 patients (2012 Canadian dollars). Costs for ‘‘providing adjuvant chemotherapy’’ include costs of treating any resulting
toxicity. Costs ‘‘incurred following distant recurrence’’ exclude costs incurred during last 3 mo of life.
z Life-years and QALYs per 1000 patients.
y ICER, ICER for the strategy in question versus the next-less-expensive nondominated strategy. Where ICER is not provided: ‘‘D’’ ¼ strategy is
dominated (more costly and less effective than at least one other strategy). Final three columns report the probability that the strategy in
question is the most cost-effective at a willingness-to-pay value of $20,000, $50,000, or $100,000, respectively, for a QALY.
J Additional events per 1000 patients compared with not providing 21-gene assay.
z Additional costs per 1000 patients compared with not providing 21-gene assay (2012 Canadian dollars).
# Additional life-years and QALYs per 1000 patients compared with not providing 21-gene assay.
 ICER, ICER for providing versus not providing the 21-gene assay to patients in the respective Adjuvant! Online risk group. Final three
columns report the probability that the 21-gene assay is cost-effective for that Adjuvant! Online risk group at a willingness-to-pay value of
$20,000, $50,000, or $100,000, respectively, for a QALY.
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vant chemotherapy is cost-effective is less than 39% for 21-gene
assay low-risk patients but is more than 98% for 21-gene assay
high-risk patients.
For 21-gene assay intermediate-risk patients, the cost-
effectiveness of adjuvant chemotherapy is conditional upon
Adjuvant! Online risk. For patients at low Adjuvant! Online risk
and intermediate 21-gene assay risk, chemotherapy has an ICER
of $44,088 per QALY. Although this ICER is below a typical
willingness-to-pay threshold of $50,000 per QALY, the probability
that chemotherapy is cost-effective at this willingness-to-pay
threshold is just 50.59%. The cost-effectiveness of chemotherapy
is therefore highly uncertain for patients at low Adjuvant! Online
risk and intermediate 21-gene assay risk. For patients at inter-
mediate or high Adjuvant! Online risk and intermediate 21-gene
assay risk, chemotherapy is likely to be cost-effective, with anICER of $1,776 per QALY (probability cost-effective 77.65%) or
$1,778 per QALY (82.31%) respectively.Conclusions
The 21-gene assay appears to be cost-effective for Ontario
patients with lymph node–negative, estrogen receptor– and/or
progesterone receptor–positive, HER2/neu-negative early breast
cancer. It is most cost-effective for patients considered to be at
intermediate or high risk using Adjuvant! Online.
In the opinion of the expert panel convened by the Ontario
Ministry of Health and Long-Term Care, the results of Adjuvant!
Online can often be approximated by clinician judgment.
It follows that in cases in which Adjuvant! Online is not used
as an initial risk stratification tool, the 21-gene assay is most
Table 3 – Outcomes, costs, effectiveness, and cost-effectiveness of providing adjuvant chemotherapy.
Adjuvant!
Online risk
group
21-gene
assay risk
group (if
provided)
Adjuvant
chemotherapy
(if provided) Outcomes Costs ($ million)y
10- y
dist.
rec.
10-y
death
Providing
21-gene
assay
Providing
adjuvant
chemo
Incurred
prior to
dist. rec.
Incurred
following
dist. rec.
Low Low None 25 21 4.33 0.00 6.94 0.81
CMF 35 29 4.33 2.54 6.49 1.13
Intermediate None 57 47 4.33 0.00 6.70 1.75
TC 41 33 4.33 5.20 6.45 1.31
High None 243 203 4.33 0.00 5.39 6.54
FEC-D 60 49 4.33 7.43 6.30 1.87
None None 66 54 0.00 0.00 6.62 2.04
CMF 45 37 0.00 2.54 6.41 1.45
Intermediate Low None 42 34 4.33 0.00 6.82 1.30
CMF 43 35 4.33 2.54 6.44 1.36
Intermediate None 131 108 4.33 0.00 6.16 3.77
TC 57 47 4.33 5.20 6.33 1.78
High None 448 382 4.33 0.00 4.18 10.55
FEC-D 67 55 4.33 7.43 6.24 2.10
None None 202 168 0.00 0.00 5.65 5.64
TC 56 45 0.00 5.20 6.33 1.76
High Low None 41 34 4.33 0.00 6.82 1.29
CMF 43 35 4.33 2.54 6.43 1.36
Intermediate None 131 108 4.33 0.00 6.15 3.80
TC 58 47 4.33 5.20 6.32 1.80
High None 448 381 4.33 0.00 4.17 10.58
FEC-D 69 56 4.33 7.43 6.23 2.14
None None 239 199 0.00 0.00 5.40 6.51
FEC-D 51 42 0.00 7.43 6.37 1.63
(Continued on next page)
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distant recurrence.
Adjuvant chemotherapy appears cost-effective for 21-gene
assay high-risk patients, but not for low-risk patients. For
patients at intermediate 21-gene assay risk, adjuvant chemo-
therapy appears cost-effective for those considered to be at
intermediate or high risk using Adjuvant! Online. For 21-gene
assay intermediate-risk patients who otherwise appear to be at
low risk of distant recurrence, the cost-effectiveness of adjuvant
chemotherapy is uncertain.
Our findings are consistent with those of existing cost-
effectiveness analyses of the 21-gene assay [16,39–44]. With the
exception of the recent analysis by Reed et al. [44], however, these
previous analyses share a number of limitations: none considers
provision of the 21-gene assay conditional upon Adjuvant! Online
risk; most conflate the intermediate and high 21-gene assay risk
groups; and all implicitly assume that the 21-gene assay replaces,
rather than complements, Adjuvant! Online or clinician judg-
ment in adjuvant chemotherapy decision making. The Reed et al.
analysis addresses these limitations but has a number of limi-
tations of its own. In particular, it makes flawed assumptions in
its interpretation of the data from Lo et al. that inform the
proportion of patients assumed to receive chemotherapy: first,
that a recommendation to provide hormonal therapy in the
absence of the 21-gene assay results necessarily implies that
the patient is low risk; and second, that a clinician’s recommen-
dation of ‘‘equipoise’’ instead represents a recommendation to
provide chemotherapy. The Reed et al. analysis also makes the
assumption that in the absence of the 21-gene assay results, no
low-risk patients would receive chemotherapy but everyintermediate- or high-risk patient would receive chemotherapy
(this assumption in particular serves to exaggerate the benefit of
the 21-gene assay). Critically, no existing analyses, including the
Reed et al. analysis, directly evaluate the cost-effectiveness of
adjuvant chemotherapy for patients in specific risk categories.
Our analysis comprehensively addresses all these limitations.
Nevertheless, our analysis also has limitations. Most notably,
the allocation of patients among risk categories and the esti-
mates of the baseline risk of distant recurrence were derived
from unpublished retrospective data, while the relative risk
estimates were derived by using retrospective data and the
results of trials that may not be directly comparable. Our model
also did not consider local recurrence or the possibility of minor
or long-term adverse events resulting from chemotherapy, while
the impact of the 21-gene assay on clinician decision making was
derived from a small study conducted outside the Ontario
context. Finally, our analysis does not control for the potential
confounding effects of HER2/neu positivity across the key vali-
dation studies [6,7]. With the introduction of trastuzumab, HER2/
neu-positive patients currently undertake a treatment pathway
that is distinct from that taken by HER2/neu-negative patients,
and so these patients are generally not candidates for the 21-gene
assay. It is unclear what effect removing HER2/neu-positive
patients would have on the prognostic and predictive value of
the 21-gene assay [6].
Our findings will be of considerable interest to policymakers
and health care providers. In the United States, the cost of the 21-
gene assay is currently covered by Medicare and some major
insurance companies [45]. In the United Kingdom, the National
Institute for Health and Care Excellence (formerly the National
Table 3 – continued
Effectivenessz Cost-effectiveness of adjuvant chemotherapyy
Incurred during last
3 mo of life
Total lifetime
costs ($ million)
Life-
years
QALYs ICER Prob. CE
($20k) (%)
Prob. CE
($50k) (%)
Prob. CE
($100k) (%)
0.79 12.67 15,365 11,930 D 11.28 15.43 17.34
1.10 15.39 15,140 11,691
1.71 14.28 14,846 11,519 $44,088 40.96 50.59 54.41
1.28 18.37 15,039 11,611
6.40 22.45 12,067 9,317 CE 98.99 99.41 99.54
1.83 21.56 14,732 11,368
1.99 10.65 14,689 11,394 $7,389 63.22 68.65 70.73
1.42 11.82 14,965 11,552
1.27 13.51 15,095 11,716 D 34.12 37.52 38.85
1.32 15.78 15,015 11,592
3.69 17.74 13,696 10,607 $1,776 73.79 77.65 78.85
1.73 19.16 14,781 11,407
10.34 29.20 9,506 7,293 CE 99.99 100.00 100.00
2.05 21.94 14,608 11,269
5.51 16.80 12,622 9,757 CE 99.79 99.87 99.89
1.72 15.01 14,794 11,417
1.26 13.49 15,100 11,720 D 32.66 36.19 37.58
1.33 15.80 15,010 11,588
3.71 17.79 13,685 10,599 $1,778 78.74 82.31 83.91
1.76 19.21 14,769 11,397
10.37 29.25 9,494 7,283 CE 100.00 100.00 100.00
2.09 22.02 14,586 11,252
6.37 18.28 12,097 9,341 CE 100.00 100.00 100.00
1.59 17.02 14,865 11,474
CE, cost-effectiveness; chemo, chemotherapy; CMF, oral cyclophosphamide 100 mg/m2, methotrexate 40 mg/m2, and 5-fluorouracil 600 mg/m2,
given 4-weekly for six cycles; dist., distant; FEC-D, 5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2, given
3-weekly for three cycles, followed by docetaxel 100 mg/m2 given 3-weekly for three cycles; ICER, incremental cost-effectiveness ratio; Prob.,
probability; QALY, quality-adjusted life-year; rec., recurrence; TC, docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2, given 3-weekly for
four cycles.
 Number of events per 1000 patients.
y Costs per 1000 patients (2012 Canadian dollars). Costs for ‘‘providing adjuvant chemotherapy’’ include costs of treating any resulting toxicity.
Costs ‘‘incurred following distant recurrence’’ exclude costs incurred during last 3 mo of life.
z Life-years and QALYs per 1000 patients.
y ICER, ICER for providing (vs. not providing) adjuvant chemotherapy. Where ICER is not provided: ‘‘D’’ ¼ adjuvant chemotherapy is dominated
(more costly and less effective); ‘‘CE’’ ¼ adjuvant chemotherapy is less costly and more effective. Final three columns report the probability
that adjuvant chemotherapy is cost-effective at a willingness-to-pay for a QALY of $20,000, $50,000, or $100,000, respectively.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 7 2 9 – 7 3 9 737Institute for Health and Clinical Excellence) recently issued
preliminary guidance that recommended funding the 21-gene
assay through the National Health Service (NHS) only in cases
where a patient is initially assessed as being at ‘‘intermediate
risk,’’ where the decision to provide chemotherapy remains
‘‘unclear,’’ and where the 21-gene assay is provided by the
manufacturer to the NHS at the price offered through a ‘‘con-
fidential arrangement agreed with NICE’’ [46]. In Ontario, based in
part on our findings, the Ontario Health Technology Advisory
Committee has proposed that the 21-gene assay be funded for
patients as part of a field evaluation, with the aim of evaluating
‘‘further correlations between [the 21-gene assay] and Adjuvant!
Online and other clinical variables, as well as the clinical impact
of [the 21-gene assay] on patient and practitioner decision-
making’’ [47].
Our findings will also be of interest to clinicians faced with a
climate of constrained resources and the difficult decision of
whether to provide chemotherapy, particularly to patients in theintermediate 21-gene assay risk group. This clinical uncertainty
is the primary motivation behind the ongoing TAILORx trial
[11,12].
While the 21-gene assay is the first genomic-based breast
cancer decision aid to be evaluated by the Ontario Ministry of
Health and Long-Term Care, and remains the only genomic-
based breast cancer decision aid used in clinical practice in
Ontario, a number of alternative decision aids have recently
become available [48–50]. Our modeling framework may be
adapted to evaluate the clinical- and cost-effectiveness of these
and future genomic-based breast cancer decision aids, and
potentially guide adjuvant chemotherapy decisions on the
basis of multiple genomic- and non–genomic-based decision aids
used in conjunction. In the meantime, our analysis pro-
vides policymakers and clinicians with guidance, based on
the best evidence currently available, on the clinical- and
cost-effective provision of the 21-gene assay and adjuvant
chemotherapy.
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